Top Markets
#1 Black Phoenix Black Phoenix +354.83%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +80.06%
#4 Gold Park Gold Park +60.52%
#5 Acurast Acurast +38.24%
#6 OpenEden OpenEden +36.58%
#7 BasedHype BasedHype +27.21%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +23.14%
#9 Cryptopia Cryptopia +21.54%
#10 Avantis Avantis +20.59%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Purple Biotech Ltd. Purple Biotech Ltd.

Purple Biotech Ltd.

PPBT
Rank in Stocks #40642
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Share Price
$0.00323826
Last synced: 2026-08-12
Market Cap
$104.81K
Change (1 day)
0.00%
Change (1 year)
-70.42%
Country
IL
Trade Purple Biotech Ltd. (PPBT)

Category

Healthcare
Revenue for Purple Biotech Ltd. (PPBT)
Revenue in Aug 2026 TTM: 0
According to Purple Biotech Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Purple Biotech Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE